These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 18539537

  • 1. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis.
    Wiesemann E, Deb M, Hemmer B, Radeke HH, Windhagen A.
    Clin Immunol; 2008 Sep; 128(3):306-13. PubMed ID: 18539537
    [Abstract] [Full Text] [Related]

  • 2. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
    Wiesemann E, Deb M, Trebst C, Hemmer B, Stangel M, Windhagen A.
    Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
    [Abstract] [Full Text] [Related]

  • 3. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
    Marckmann S, Wiesemann E, Hilse R, Trebst C, Stangel M, Windhagen A.
    Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628
    [Abstract] [Full Text] [Related]

  • 4. The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients.
    Bartosik-Psujek H, Stelmasiak Z.
    Clin Neurol Neurosurg; 2006 Oct; 108(7):644-7. PubMed ID: 16343740
    [Abstract] [Full Text] [Related]

  • 5. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H.
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [Abstract] [Full Text] [Related]

  • 6. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
    Nicoletti F, Di Marco R, Patti F, Zaccone P, L'Episcopo MR, Reggio E, Xiang M, Nicoletti A, Reggio A.
    Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
    [Abstract] [Full Text] [Related]

  • 7. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
    Mei FJ, Osoegawa M, Ochi H, Minohara M, Nan S, Murai H, Ishizu T, Taniwaki T, Kira J.
    J Neurol Sci; 2006 Jul 15; 246(1-2):71-7. PubMed ID: 16581087
    [Abstract] [Full Text] [Related]

  • 8. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H, Feng-Jun M, Osoegawa M, Minohara M, Murai H, Taniwaki T, Kira J.
    J Neurol Sci; 2004 Jul 15; 222(1-2):65-73. PubMed ID: 15240198
    [Abstract] [Full Text] [Related]

  • 9. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H.
    J Neuroimmunol; 2005 Feb 15; 159(1-2):155-64. PubMed ID: 15652415
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
    Carrieri PB, Ladogana P, Di Spigna G, de Leva MF, Petracca M, Montella S, Buonavolontà L, Florio C, Postiglione L.
    Immunopharmacol Immunotoxicol; 2008 Feb 15; 30(4):1-9. PubMed ID: 18686100
    [Abstract] [Full Text] [Related]

  • 11. Could cytokines levels or adhesion molecules expression be predictor of IFN-beta treatment response in multiple sclerosis patients?
    Sega S, Horvat A, Rot U, Wraber B, Ihan A.
    Clin Neurol Neurosurg; 2008 Nov 15; 110(9):947-50. PubMed ID: 18396372
    [Abstract] [Full Text] [Related]

  • 12. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
    Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Govoni V, Caniatti L, Paolino E, Tola MR, Granieri E, Baricordi OR.
    J Neuroimmunol; 2004 Mar 15; 148(1-2):206-11. PubMed ID: 14975603
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
    Perini P, Tiberio M, Sivieri S, Facchinetti A, Biasi G, Gallo P.
    Eur Cytokine Netw; 2000 Mar 15; 11(1):81-6. PubMed ID: 10705303
    [Abstract] [Full Text] [Related]

  • 14. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K, Reder AT.
    Mult Scler; 2007 May 15; 13(4):459-70. PubMed ID: 17463069
    [Abstract] [Full Text] [Related]

  • 15. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?
    Drulovic J, Savic E, Pekmezovic T, Mesaros S, Stojsavljevic N, Dujmovic-Basuroski I, Kostic J, Vasic V, Mostarica Stojkovic M, Popadic D.
    J Neuroimmunol; 2009 Oct 30; 215(1-2):90-5. PubMed ID: 19695714
    [Abstract] [Full Text] [Related]

  • 16. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F.
    Mult Scler; 2008 Jun 30; 14(5):622-30. PubMed ID: 18424480
    [Abstract] [Full Text] [Related]

  • 17. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
    Weber F, Polak T, Günther A, Kubuschok B, Janovskaja J, Bitsch A, Poser S, Rieckmann P.
    Ann Neurol; 1998 Jul 30; 44(1):27-34. PubMed ID: 9667590
    [Abstract] [Full Text] [Related]

  • 18. The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis.
    Hedegaard CJ, Krakauer M, Bendtzen K, Sørensen PS, Sellebjerg F, Nielsen CH.
    Clin Immunol; 2008 Oct 30; 129(1):80-9. PubMed ID: 18653385
    [Abstract] [Full Text] [Related]

  • 19. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P, Romano MR, Boccardi B, Lombardo F, Moscato G, Mosti S, Baldini C, Nuti S, Meucci G, Rossi B.
    Rev Neurol; 2008 Oct 30; 29(10):893-9. PubMed ID: 10637835
    [Abstract] [Full Text] [Related]

  • 20. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.
    Azoulay D, Mausner-Fainberg K, Urshansky N, Fahoum F, Karni A.
    J Neuroimmunol; 2009 Jun 25; 211(1-2):114-9. PubMed ID: 19419774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.